Close Menu

NEW YORK – The US Food and Drug Administration has approved GlaxoSmithKline's PARP inhibitor niraparib (Zejula) as a first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of their biomarker status.

Less than 50 percent of women with advanced ovarian cancer live for five years. "This expanded indication means that many more women with this devastating disease can receive earlier treatment with Zejula, which can extend the time it takes for their cancer to progress," GSK CSO Hal Barron said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.